NCT06574620View on ClinicalTrials.gov

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

NANot yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2031

Conditions
Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
GENETIC

Genetic testing

Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.

PROCEDURE

Optional biopsy

Optional collection of tumour tissue and normal tissue after the last dose of treatment.

PROCEDURE

Tissue collection

Collection of tumour tissue and normal tissue from biopsy or standard resection surgery prior to the first dose of treatment.

Trial Locations (1)

V5Z 4E6

BC Cancer, Vancouver

All Listed Sponsors
collaborator

Terry Fox Research Institute

OTHER

collaborator

BC Cancer Foundation

OTHER

lead

British Columbia Cancer Agency

OTHER

NCT06574620 - Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment | Biotech Hunter | Biotech Hunter